722.8 USD
-0.87 (-0.12%)
722.8 USD
0 (0%)
REGN gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. REGN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. REGN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make REGN suitable for value investing!
1. Profitability
1.1 Basic Checks
REGN had positive earnings in the past year.
REGN had a positive operating cash flow in the past year.
REGN had positive earnings in each of the past 5 years.
In the past 5 years REGN always reported a positive cash flow from operatings.
1.2 Ratios
REGN has a Return On Assets of 11.40%. This is amongst the best in the industry. REGN outperforms 94.38% of its industry peers.
REGN has a better Return On Equity (14.79%) than 94.94% of its industry peers.
REGN has a Return On Invested Capital of 8.69%. This is amongst the best in the industry. REGN outperforms 94.19% of its industry peers.
The Average Return On Invested Capital over the past 3 years for REGN is significantly below the industry average of 18.60%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
The Profit Margin of REGN (32.13%) is better than 96.63% of its industry peers.
In the last couple of years the Profit Margin of REGN has grown nicely.
REGN has a better Operating Margin (27.61%) than 96.44% of its industry peers.
REGN's Operating Margin has declined in the last couple of years.
REGN's Gross Margin of 86.28% is amongst the best of the industry. REGN outperforms 88.20% of its industry peers.
REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
Compared to 1 year ago, REGN has about the same amount of shares outstanding.
The number of shares outstanding for REGN has been reduced compared to 5 years ago.
REGN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.26 indicates that REGN is not in any danger for bankruptcy at the moment.
The Altman-Z score of REGN (7.26) is better than 77.72% of its industry peers.
The Debt to FCF ratio of REGN is 0.70, which is an excellent value as it means it would take REGN, only 0.70 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.70, REGN belongs to the top of the industry, outperforming 94.38% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
REGN has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: REGN underperforms 62.17% of its industry peers.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.26 |
ROIC/WACC1.03
WACC8.48%
2.3 Liquidity
A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
The Current ratio of REGN (4.06) is comparable to the rest of the industry.
REGN has a Quick Ratio of 3.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN has a Quick ratio of 3.51. This is comparable to the rest of the industry: REGN outperforms 44.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
The Earnings Per Share has been growing by 13.12% on average over the past years. This is quite good.
REGN shows a small growth in Revenue. In the last year, the Revenue has grown by 2.89%.
Measured over the past years, REGN shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
Based on estimates for the next years, REGN will show a small growth in Earnings Per Share. The EPS will grow by 6.38% on average per year.
Based on estimates for the next years, REGN will show a small growth in Revenue. The Revenue will grow by 5.63% on average per year.
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.38%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.63%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.06, REGN is valued correctly.
REGN's Price/Earnings ratio is rather cheap when compared to the industry. REGN is cheaper than 94.94% of the companies in the same industry.
REGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.37.
REGN is valuated correctly with a Price/Forward Earnings ratio of 16.27.
Compared to the rest of the industry, the Price/Forward Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 94.94% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.20, REGN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.06 | ||
| Fwd PE | 16.27 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaper than 94.94% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, REGN is valued cheaply inside the industry as 94.76% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.57 | ||
| EV/EBITDA | 14.44 |
4.3 Compensation for Growth
The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.22
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
5. Dividend
5.1 Amount
With a yearly dividend of 0.45%, REGN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 69.91, REGN pays a better dividend. On top of this REGN pays more dividend than 98.31% of the companies listed in the same industry.
With a Dividend Yield of 0.45, REGN pays less dividend than the S&P500 average, which is at 2.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.45% |
5.2 History
REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
722.8
-0.87 (-0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.24%
Inst Owner Change-0.5%
Ins Owners1.89%
Ins Owner Change0.24%
Market Cap75.97B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80.59
Price Target774.53 (7.16%)
Short Float %2.81%
Short Ratio2.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.45% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)3.57%
PT rev (3m)3.91%
EPS NQ rev (1m)11.32%
EPS NQ rev (3m)14.58%
EPS NY rev (1m)6.84%
EPS NY rev (3m)6.99%
Revenue NQ rev (1m)3.15%
Revenue NQ rev (3m)4.24%
Revenue NY rev (1m)1.81%
Revenue NY rev (3m)1.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.06 | ||
| Fwd PE | 16.27 | ||
| P/S | 5.33 | ||
| P/FCF | 19.57 | ||
| P/OCF | 14.98 | ||
| P/B | 2.45 | ||
| P/tB | 2.57 | ||
| EV/EBITDA | 14.44 |
EPS(TTM)45.01
EY6.23%
EPS(NY)44.42
Fwd EY6.15%
FCF(TTM)36.93
FCFY5.11%
OCF(TTM)48.25
OCFY6.68%
SpS135.56
BVpS294.56
TBVpS281.42
PEG (NY)N/A
PEG (5Y)1.22
Graham Number546.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.26 |
F-Score5
WACC8.48%
ROIC/WACC1.03
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.38%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.63%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-14.02%
EBIT Next 3Y4.25%
EBIT Next 5Y10.18%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 7 / 10 to REGN.
What is the valuation status for REGN stock?
ChartMill assigns a valuation rating of 7 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Undervalued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for REGN stock?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to decline by -6.32% in the next year.